Dipeptidyl Peptidase II (DPPII): Emerging Functions, Disease Links, and Future Research Directions

Dipeptidyl peptidase II (DPPII) has emerged as an intriguing yet underexplored member of the proline-specific dipeptidyl peptidase family, a group of enzymes increasingly recognized for their roles in intracellular peptide processing and cellular regulation. Unlike membrane-associated DPPs such as DPPIV or fibroblast activation protein, DPPII resides within acidic vesicular compartments where it selectively cleaves N-terminal dipeptides from peptides containing proline or alanine in the penultimate position. Although its exact physiological function remains unresolved, a growing body of research suggests that DPPII participates in diverse biological processes, including cell differentiation, protection from apoptosis, degradation of structural peptides, and the turnover of neuroactive fragments. Altered DPPII expression in inflammatory conditions, neurodegenerative disorders, tissue remodeling, and various cancers highlights its potential involvement in disease-related pathways. As interest in intracellular proteases expands, DPPII stands out as a promising focus for future studies aimed at understanding proteolytic networks, identifying disease biomarkers, and exploring new avenues for therapeutic intervention. Consolidating the fragmented literature surrounding DPPII will be critical for unlocking its broader significance in both health and disease.

Introduction: Why DPPII Is Gaining Scientific Attention

Dipeptidyl peptidase II (DPPII) has emerged as an important, though still underexplored, enzyme within the expanding family of proline-specific dipeptidyl peptidases (DPPs). Over the past decade, researchers have increasingly recognized that the regulation of peptide hormones, neuropeptides, and signaling molecules often depends on precise N-terminal trimming—particularly at sites where proline occupies the penultimate position. This shift in understanding has brought renewed attention to DPPII, along with its well-known counterparts DPPIV, fibroblast activation protein α (FAP), DPP8, and DPP9. Collectively, these enzymes form a protease network with substantial influence over cellular communication, immune function, and metabolic regulation.

What distinguishes DPPII is its intracellular localization to the vesicular system and its preference for releasing N-terminal dipeptides at acidic pH. Unlike DPPIV, which is expressed on the cell surface and widely known for its role in incretin hormone processing, DPPII operates within endosomal and lysosomal compartments. This unique positioning suggests a fundamentally different biological role—one that may extend beyond routine protein degradation and into the regulation of intracellular signaling or stress responses.

Although the full physiological function of DPPII remains elusive, several lines of evidence indicate that the enzyme may contribute to key processes such as cell differentiation, protection from apoptosis, and the turnover of structural proteins like collagen and myofibrillar components. These activities imply that DPPII could influence tissue remodeling, muscle maintenance, or neuronal signaling pathways. Moreover, the enzyme’s ability to process short neuropeptides highlights its potential involvement in modulating communication between cells in both the central and peripheral nervous systems.

Interest in DPPII has intensified as studies reveal changes in its expression levels and distribution under pathological conditions. Alterations in DPPII activity have been observed in inflammatory states, degenerative processes, and certain disease-related tissues, providing clues that the enzyme’s regulatory functions may become dysregulated during illness. This makes DPPII an intriguing candidate for further investigation—not only to clarify its biological significance but also to explore whether it may serve as a biomarker or therapeutic target in the future.

As research continues, consolidating the fragmented literature surrounding DPPII becomes essential. Understanding how this enzyme fits within the broader DPP family may unlock new insights into intracellular proteolysis and its role in health and disease.

Understanding DPPII: Structure, Classification, and Enzymatic Properties

Dipeptidyl peptidase II (DPPII), classified under EC 3.4.14.2, is an intracellular serine protease belonging to the broader family of proline-specific dipeptidyl peptidases (DPPs). Unlike the more widely studied DPPIV, which resides on the cell surface, DPPII is localized primarily within acidic vesicular compartments such as lysosomes and endosomes. This intracellular positioning is essential for its biochemical functionality and distinguishes DPPII from other family members with roles in extracellular or membrane-associated peptide regulation.

Structurally, DPPII is synthesized as a zymogen that undergoes proteolytic maturation within vesicular pathways. It functions as a homodimer or multimeric complex, which contributes to its enzymatic stability in low-pH environments. Its catalytic machinery belongs to the serine protease class, relying on a classical serine-based catalytic triad for peptide bond hydrolysis. Despite this classification, DPPII behaves similarly to some cysteine DPPs in terms of substrate specificity, reflecting the complex evolutionary relationships within the DPP family.

The defining enzymatic characteristic of DPPII is its strict preference for cleaving N-terminal dipeptides from polypeptides where the penultimate residue is proline or alanine. Its optimal activity occurs in acidic conditions, typically around pH 4.5–5.5, aligning with the environment of lysosomal vesicles. This pH-dependent functionality ensures that DPPII remains largely inactive in the neutral cytosol, preventing unwanted proteolysis and maintaining strict spatial control over its enzymatic influence.

DPPII’s substrate specificity suggests involvement in intracellular peptide turnover, particularly of short-lived peptides, signaling fragments, and partially degraded proteins generated during lysosomal proteolysis. In contrast to DPPIV—which modulates systemic hormone and chemokine activity—DPPII’s intracellular role may be more closely related to maintaining proteostasis, regulating vesicular trafficking, or processing peptides involved in stress responses.

Interestingly, DPPII shares overlapping biochemical properties with DPP8 and DPP9, two cytosolic enzymes that also recognize X-Pro motifs. However, DPPII is unique in its strong pH dependency and vesicular confinement, suggesting that each enzyme contributes distinctly to cellular proteolytic networks. Comparative enzymology studies continue to clarify these relationships and highlight DPPII as an essential, though still understudied, component of intracellular protein regulation.

Fig 1. DPPII: Key Structural and Enzymatic Features

As the field advances, defining DPPII’s precise structural and functional characteristics will be crucial for understanding not only its biochemical behavior but also its broader implications in health, disease, and therapeutic targeting.

Biological Functions: What Current Research Suggests

Although the complete physiological role of dipeptidyl peptidase II (DPPII) remains unresolved, mounting evidence suggests that this intracellular protease participates in several fundamental biological processes. Its ability to cleave N-terminal dipeptides—particularly when the penultimate position contains proline or alanine—positions DPPII at a critical junction between peptide degradation, vesicular processing, and intracellular signaling. Because DPPII operates optimally at acidic pH, its activity is naturally integrated into lysosomal and endosomal pathways responsible for protein turnover and cellular homeostasis.

One of the most frequently proposed roles of DPPII is its participation in cell differentiation. Early studies showed fluctuations in DPPII levels during the maturation of immune cells, myoblasts, and certain epithelial tissues, hinting that the enzyme may regulate peptide signals required for lineage commitment or progression. These associations suggest that DPPII could influence transcriptional programs indirectly by modifying peptide substrates involved in differentiation.

Another proposed function involves protection against apoptosis. Because DPPII resides in vesicles that respond dynamically to cellular stress, some evidence indicates that the enzyme may help maintain structural integrity of the lysosomal system or modulate peptide fragments that accumulate during stress responses. While the precise mechanism is not fully understood, DPPII deficiency or inhibition has been correlated with increased susceptibility to cell death in certain cell models, leading researchers to speculate that it contributes to intracellular survival pathways.

DPPII has also been implicated in the degradation of collagen fragments and myofibrillar proteins, highlighting a potential role in tissue remodeling and muscle maintenance. By processing partially digested structural proteins, DPPII may assist in clearing turnover products within lysosomes, thereby supporting normal proteostasis. This function aligns with the enzyme’s preference for short oligopeptides, which often arise as intermediates during lysosomal breakdown.

Additionally, the enzyme has been suggested to degrade short neuropeptides, placing DPPII within broader neurochemical networks. Its ability to process neuroactive peptides may influence signaling dynamics in neural or neuroendocrine tissues, though this remains an area lacking comprehensive characterization.

Importantly, shifts in DPPII expression under pathological conditions have offered indirect clues about its biological relevance. Elevated or diminished enzyme levels observed in inflammatory states, degenerative disorders, and certain cancers indicate that DPPII may participate in disease-related pathways, either as a compensatory mechanism or as a contributor to pathology.

Collectively, current data portray DPPII as an intracellular protease with diverse functional potential, operating at the intersection of peptide metabolism, cell survival, and tissue remodeling. Continued research is essential to fully elucidate its contributions to both normal physiology and disease processes.

DPPII in Health and Disease: Clues From Expression Patterns

As research on dipeptidyl peptidase II (DPPII) expands, the enzyme’s expression patterns across tissues and disease states have become an important window into its biological relevance. While the precise physiological function of DPPII remains incompletely defined, fluctuating enzyme levels observed under pathological conditions provide valuable clues regarding its potential involvement in inflammation, tissue remodeling, neurodegenerative processes, and even tumor biology.

One of the most notable observations is that DPPII expression often increases in tissues undergoing active remodeling or repair. Because DPPII can degrade short peptide fragments derived from collagen or cytoskeletal proteins, elevated enzyme activity in wound healing or fibrotic conditions suggests a role in clearing degradation intermediates. This function aligns with its localization in lysosomal compartments, where it contributes to the proteolytic machinery responsible for maintaining proteostasis during stress or recovery.

In the context of inflammation, DPPII expression has been found to shift in immune-related tissues, including lymphoid organs and activated leukocytes. Since many immune processes rely on tightly controlled peptide signaling, altered DPPII levels may reflect changes in intracellular peptide processing during cytokine production or immune cell activation. Some studies have noted increased DPPII activity in chronic inflammatory diseases, hinting at compensatory responses or dysregulation of peptide turnover pathways.

DPPII has also been implicated in degenerative and age-related conditions. Neuronal tissues, which depend heavily on efficient peptide degradation, show altered DPPII distribution in certain neurodegenerative models. As DPPII can process short neuropeptides and fragments derived from neuronal proteins, variations in its expression may correlate with impaired lysosomal function—an emerging hallmark of neurodegenerative disease.

Perhaps most intriguing is the potential connection between DPPII and cancer biology. Shifts in DPPII expression have been reported in several tumor types, though the implications vary. In certain cancers, elevated DPPII activity may reflect increased metabolic turnover or adaptation to acidic microenvironments. Alternatively, reduced expression in other tumor contexts might indicate that DPPII contributes to cell survival pathways that cancer cells seek to suppress. These inconsistent patterns underscore the complexity of DPPII’s role and the need for more targeted mechanistic studies.

Overall, the observed changes in DPPII levels across a range of pathological settings suggest that the enzyme participates actively in disease-associated processes rather than serving merely as a housekeeping protease. Understanding these expression patterns will be instrumental in determining whether DPPII may serve as a biomarker, a therapeutic target, or an indicator of intracellular proteolytic health.

Future Directions: Why DPPII Matters for Biomedical Research

As scientific interest in dipeptidyl peptidase II (DPPII) continues to grow, it is becoming increasingly clear that this enzyme holds untapped potential for advancing biomedical research. Although DPPII has historically received less attention than other members of the dipeptidyl peptidase family, emerging findings suggest that it may play influential roles in intracellular proteolysis, cellular homeostasis, immune responses, and disease-related processes. These clues highlight the need for deeper investigation into DPPII’s molecular functions, regulatory mechanisms, and potential applications in diagnostics and therapeutics.

One of the most promising future directions lies in defining the precise physiological function of DPPII. The enzyme’s preference for cleaving N-terminal dipeptides from peptides containing proline or alanine, combined with its vesicular localization, indicates that it may regulate small peptide intermediates within lysosomes. Understanding these substrates—many of which may influence signaling pathways, stress responses, or cellular metabolism—could uncover novel mechanisms of intracellular communication.

Investigating DPPII’s relationship with cell survival and differentiation pathways also holds considerable potential. Since DPPII levels shift during differentiation and cellular stress, future studies may reveal how the enzyme affects lineage commitment, apoptosis resistance, or adaptation to metabolic changes. This knowledge could have implications for regenerative medicine, tissue engineering, and the study of developmental disorders.